Prostate neoplasm
MONDO:0021259A neoplasm (disease) that involves the prostate gland.
Also known as: neoplasm of prostate, neoplasm of prostate gland, neoplasm of the prostate, prostate gland neoplasm, prostate gland neoplasm (disease), prostate gland tumor, prostate gland tumour, prostate tumor
3585 clinical trials for this condition and its sub-types, 124 tagged with Prostate neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Prostate neoplasm
-
Prostate cancer 1,913 trials · 2,217 incl. sub-types
5 sub-types
- Prostate carcinoma 394 trials · 1,321 incl. sub-types Sub-types →
- Prostate cancer, hereditary 1 trial · 4 incl. sub-types Sub-types →
- Malignant prostate phyllodes tumor 0 trials
- Prostate lymphoma 0 trials
- Prostate sarcoma 0 trials Sub-types →
-
Prostate neuroendocrine neoplasm 20 trials · 25 incl. sub-types
1 sub-type
- Prostate small cell carcinoma 9 trials
-
Prostate intraepithelial neoplasia 2 trials
1 sub-type
-
Benign neoplasm of prostate 0 trials
4 sub-types
- Benign prostate phyllodes tumor 0 trials
- Fibroma of prostate 0 trials
- Prostate leiomyoma 0 trials
- Prostatic adenoma 0 trials
-
Prostate phyllodes tumor 0 trials
2 sub-types
- Benign prostate phyllodes tumor 0 trials
- Malignant prostate phyllodes tumor 0 trials
Most studied deeper sub-types
-
Could a few weeks of radiation be enough for recurrent prostate cancer?
Disease control CompletedThis early-phase trial tested a shorter course of radiation for men whose prostate cancer came back after their prostate was removed. Instead of the usual 6-7 weeks of daily radiation, researchers gave higher doses over just 2-4 weeks, focusing the strongest radiation on the tumo…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Promising prostate cancer drug apalutamide tested in chinese patients
Disease control CompletedThis study tests whether the drug apalutamide can delay prostate cancer progression in Chinese men whose cancer has stopped responding to standard hormone therapy but hasn't spread to other parts of the body. About 75 participants will receive either apalutamide or a placebo, alo…
Phase 4 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Immunotherapy combo takes on Hard-to-Treat prostate cancer
Disease control CompletedThis clinical trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to the standard hormone therapy enzalutamide (Xtandi) helps men with a type of advanced prostate cancer called metastatic castration-resistant prostate cancer (mCRPC). The study includes men …
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Vaccine-Chemo combo shows promise against spread prostate cancer
Disease control CompletedThis study tested whether adding a prostate cancer vaccine (PROSTVAC) and chemotherapy (docetaxel) to standard hormone therapy works better than hormone therapy alone for men whose prostate cancer has spread. 74 men with metastatic castration-sensitive prostate cancer took part. …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New hope for japanese men with tough prostate cancer?
Disease control CompletedThis early-phase study tested a new drug, opevesostat (MK-5684), in 7 Japanese men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The main goals were to check the drug's safety and how the body processes it. This is a first step to se…
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New combo aims to stop prostate cancer relapse after surgery
Disease control CompletedThis study tested whether adding apalutamide to standard hormone therapy after prostate removal surgery can keep prostate cancer from coming back in high-risk patients. 108 men who had surgery for non-spread prostate cancer took the drug combo for up to 2 years. Researchers check…
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Engineered immune cells take on Hard-to-Treat prostate cancer
Disease control CompletedThis early-phase study tested a new treatment called JNJ-75229414, which uses a patient's own immune cells (T cells) engineered to attack prostate cancer cells. The study involved 15 men with metastatic castration-resistant prostate cancer that had already been treated with other…
Phase 1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New prostate cancer drug tested in small chinese study
Disease control CompletedThis early-phase study tested a new drug called MK-5684 (opevesostat) in 14 Chinese men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The main goals were to check the drug's safety and how the body processes it. Participants took the…
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Promising drug combo slows advanced prostate cancer in major trial
Disease control CompletedThis study tested whether adding darolutamide to standard hormone therapy helps men with prostate cancer that has spread to other parts of the body. 669 men participated. The goal was to see if the combination delays cancer growth or death. Results showed improvement in progressi…
Phase 3 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Prostate cancer patients may ditch painful hormone shots, study hints
Disease control CompletedThis study looked at whether men with advanced prostate cancer could safely stop their regular hormone injections (like leuprolide) and rely only on the pills abiraterone and prednisone to keep testosterone at very low levels. 31 men participated. The goal was to see if testoster…
Phase 2 • Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
New hope for Hard-to-Treat prostate cancer? early trial underway
Disease control CompletedThis early-stage trial tested a new drug called CC-94676 in 131 men with metastatic castration-resistant prostate cancer, a type that has stopped responding to standard hormone therapy. The main goal was to check safety and find the right dose, while also looking for signs that t…
Phase 1 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug shows promise for tough prostate cancer
Disease control CompletedThis study tested a drug called niraparib in 289 men with advanced prostate cancer that no longer responds to hormone therapy and has specific DNA repair issues. The goal was to see if the drug could shrink tumors or slow the disease. Results may help identify which patients coul…
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New combo aims to outsmart prostate cancer without Long-Term hormone shots
Disease control CompletedThis study tested whether adding the immunotherapy drug pembrolizumab (Keytruda) — alone or with an injected immune stimulant called SD-101 — to standard radiation and short-term hormone therapy could better control prostate cancer that has spread to a few spots. Twenty-three men…
Phase 2 • Sponsor: David Oh • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New cocktail of immune drugs shows promise for tough prostate cancer
Disease control CompletedThis study tested different combinations of immunotherapy drugs in 59 adults with advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if these combinations are safe and can help shrink tumors or lower PSA levels. Participants received up to fo…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Can a radioactive tracer and MRI reveal prostate Cancer's true extent?
Diagnosis CompletedResearchers are testing whether a combination of PET scans with a radioactive tracer called [18F]PSMA-1007, sodium MRI, and multiparametric MRI can accurately predict where prostate cancer is and how aggressive it is. The study enrolls men who are scheduled to have their prostate…
Phase 2 • Sponsor: Glenn Bauman • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
AI takes on prostate cancer: could a computer spot hidden spread?
Diagnosis CompletedThis study tested an artificial intelligence (AI) model designed to detect whether prostate cancer has spread to nearby lymph nodes. Researchers used digital images of lymph node tissue from 225 prostate cancer patients and compared the AI's accuracy to standard pathology reports…
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Diagnosis
Last updated Jun 27, 2026 09:04 UTC
-
New rapid PSA test could speed up prostate cancer detection
Diagnosis CompletedThis study tested a simple, rapid PSA blood test that gives results in minutes, comparing it to the standard lab PSA test. Researchers enrolled 94 men with prostate cancer or benign prostate disease. The goal was to see if the quick test is accurate enough for screening. If it wo…
Sponsor: Institut Curie • Aim: Diagnosis
Last updated Jun 27, 2026 07:59 UTC
-
New imaging agent could spot returning prostate cancer earlier
Diagnosis CompletedThis completed Phase 3 study tested a new radioactive tracer called [18F]CTT1057 for PET/CT scans in 190 men with prostate cancer whose PSA levels were rising after initial treatment. The goal was to see if the tracer could accurately locate where the cancer had returned. Partici…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Diagnosis
Last updated Jun 27, 2026 07:55 UTC
-
New PET scan agent shows promise for spotting prostate cancer
Diagnosis CompletedThis study tested a new imaging agent called [18F]CTT1057 for PET scans to see how well it can find prostate cancer tumors. 195 men with high-risk prostate cancer who were scheduled for surgery received the scan. The results were compared to tissue samples taken during surgery to…
Phase 2/3 • Sponsor: Novartis Pharmaceuticals • Aim: Diagnosis
Last updated Jun 27, 2026 07:54 UTC
-
App aims to boost cancer patients' well-being at home
Symptom relief CompletedThis completed trial tested a web-based remote monitoring platform called CONTINUUM+ CONNECT in 411 adults with metastatic breast, lung, colorectal, or prostate cancer. Patients used the platform to report symptoms and receive alerts, aiming to improve their physical health and q…
Sponsor: Centre Paul Strauss • Aim: Symptom relief
Last updated Jun 27, 2026 09:01 UTC
-
FitBit and coaching aim to boost exercise in prostate cancer patients
Symptom relief CompletedThis pilot study tested a behavioral program called PROWESS for Black and Hispanic men with prostate cancer who are on hormone therapy (ADT). The program included video or in-person sessions with a psychologist or social worker and a FitBit to track activity. The goal was to see …
Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC
-
Can a 10-Week stress program improve life for prostate cancer patients?
Symptom relief CompletedThis study tested a 10-week stress management group program for Spanish-speaking Hispanic men who had treatment for prostate cancer. The program taught relaxation, coping skills, and ways to handle stress. Researchers measured changes in quality of life, mood, and physical sympto…
Sponsor: University of Miami • Aim: Symptom relief
Last updated Jun 26, 2026 15:53 UTC
-
Robotic surgery vs standard approaches: does the platform change cancer outcomes?
Knowledge-focused CompletedResearchers at a large hospital in Seoul reviewed records from nearly 33,000 adults who had curative-intent surgery for one of seven cancers in the abdomen or pelvis: pancreatic, gastric, rectal, cervical, endometrial, kidney, or prostate. They grouped patients by whether they re…
Sponsor: Asan Medical Center • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
900 Men's quality of life checked years after prostate cancer diagnosis
Knowledge-focused CompletedThis study looks at how prostate cancer and its treatment affect quality of life three years after diagnosis. Researchers compared 900 men with prostate cancer to cancer-free men of the same age. The goal is to understand what life is like after treatment and whether patients ret…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Prostate cancer gene hunt could spot relapse early
Knowledge-focused CompletedThis study looked at genetic changes in prostate cancer samples from 84 men who had surgery. The goal was to find DNA markers that could predict if the cancer would come back or spread. By identifying these markers, doctors may one day better tailor follow-up care and treatment f…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Oxygen levels in prostate tumors may predict treatment success
Knowledge-focused CompletedThis study looked at oxygen levels inside prostate tumors in 186 men with early-stage prostate cancer. Researchers wanted to see if low oxygen (hypoxia) makes standard treatments like radiation less effective and increases the risk of cancer spreading. Participants had a special …
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Real-World data reveals treatment patterns for advanced prostate cancer
Knowledge-focused CompletedThis completed study examined how long men with metastatic castration-sensitive prostate cancer take newer hormonal therapies like abiraterone, apalutamide, and enzalutamide. Researchers analyzed Medicare claims data from over 3,000 men aged 65 and older. The goal was to describe…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Japanese prostate cancer patients tracked in Real-World registry
Knowledge-focused CompletedThis completed registry study followed nearly 1,000 Japanese men with high-risk metastatic hormone-naïve prostate cancer to see how well standard treatments work in everyday medical practice. Researchers tracked PSA levels, cancer progression, survival, and quality of life. No ne…
Sponsor: Janssen Pharmaceutical K.K. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Robot surgery vs. traditional: which prostate cancer treatment costs less?
Knowledge-focused CompletedThis study looked at the total cost of two types of prostate cancer surgery over 5 years: robot-assisted surgery using the da Vinci system and traditional open surgery. Researchers tracked medical expenses and patient outcomes in 90 men with localized prostate cancer. The goal wa…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Real-World data reveals treatment patterns for advanced prostate cancer
Knowledge-focused CompletedThis study reviewed medical records from over 1,300 men with metastatic prostate cancer that still responds to hormone therapy. Researchers wanted to see how long patients actually take the pills apalutamide or enzalutamide when prescribed by their own doctors in routine care. Th…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC
-
Robotic prostate surgery may raise throat complication risk
Knowledge-focused CompletedThis study watched 50 men having prostate surgery to see if the special positions used in robotic surgery increase pressure on the breathing tube and cause more sore throats or hoarseness. Half had robotic surgery, half had open surgery. The goal was to learn how to prevent throa…
Sponsor: Ege University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC